Silence Therapeutics/$SLN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Silence Therapeutics
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Ticker
$SLN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
116
ISIN
US82686Q1013
Website
SLN Metrics
BasicAdvanced
$281M
-
-$1.52
1.19
-
Price and volume
Market cap
$281M
Beta
1.19
52-week high
$6.00
52-week low
$1.97
Average daily volume
209K
Financial strength
Current ratio
8.814
Quick ratio
7.962
Total debt to equity
0.053
Management effectiveness
Return on assets (TTM)
-20.96%
Return on equity (TTM)
-53.13%
Valuation
Price to revenue (TTM)
10.093
Price to book
2.49
Price to tangible book (TTM)
2.73
Price to free cash flow (TTM)
-3.937
Growth
Revenue change (TTM)
-16.00%
Earnings per share change (TTM)
36.07%
3-year revenue growth (CAGR)
12.66%
3-year earnings per share growth (CAGR)
-3.10%
SLN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Silence Therapeutics stock?
Silence Therapeutics (SLN) has a market cap of $281M as of May 30, 2025.
What is the P/E ratio for Silence Therapeutics stock?
The price to earnings (P/E) ratio for Silence Therapeutics (SLN) stock is 0 as of May 30, 2025.
Does Silence Therapeutics stock pay dividends?
No, Silence Therapeutics (SLN) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Silence Therapeutics dividend payment date?
Silence Therapeutics (SLN) stock does not pay dividends to its shareholders.
What is the beta indicator for Silence Therapeutics?
Silence Therapeutics (SLN) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.